Characterization of gastrointestinal drug absorption in cynomolgus monkeys

Molecular Pharmaceutics

Volumn 5, Issue 2, 2008, Pages 340-348

  Takahashi, Masayuki ^a   Washio, Takuo ^a   Suzuki, Norio ^a   Igeta, Katsuhiro ^a   Fujii, Yoshimine ^a   Hayashi, Masahiro ^b   Shirasaka, Yoshiyuki ^c   Yamashita, Shinji ^c  

^a DAIICHI SANKYO CO   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c SETSUNAN UNIVERSITY   (Japan)

Author keywords

Cynomolgus monkey; Gastrointestinal physiology; Intestinal permeability; Oral bioavailability; Species difference; Ussing type chamber

Indexed keywords

ATENOLOL; BREAST CANCER RESISTANCE PROTEIN; FUROSEMIDE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NAPROXEN; PARACETAMOL; PROPRANOLOL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CALCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; ENZYME METABOLISM; FEMALE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRANSIT; GENE EXPRESSION; INTESTINE CELL; INTESTINE MUCOSA PERMEABILITY; MEMBRANE PERMEABILITY; MONKEY; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH EMPTYING;

ANIMALS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; INTESTINAL ABSORPTION; MACACA FASCICULARIS; PHARMACEUTICAL PREPARATIONS;

EID: 42549152142     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp700095p     Document Type: Article

References (42)

1. Chiou, W. L.; Barve, A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. 1998, 15, 1792-1795.
2. Chiou, W. L.; Jeomg, H. Y.; Chung, S. M.; Wu, T. C. Evaluation of using dogs as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm. Res. 2000, 17, 135-140.
3. Chiou, W. L.; Buehler, P. W. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm. Res. 2002, 19, 868-874.
4. Lui, C. Y.; Amidon, G. L.; Berardi, R. R.; Fleisher, D.; Youngberg, C.; Dressman, J. B. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci. 1986, 75, 271-274.
5. Yamada, I.; Goda, T.; Kawata, M.; Shiotoki, T.; Ogawa, K. Gastric acidity-dependent bioavailability of commercial sustained release preparations of indomethacin, evaluated by gastric acidity-controlled beagle dogs. Chem. Pharm. Bull. 1990, 38, 3112-3115.
6. Kanarva, H.; Klebovich, I.; Drabant, S.; Urtti, A.; Nevalainen, T. Different absorption profiles of deramciclane in man and in dog. J. Pharm. Pharmacol. 1998, 50, 1087-1093.
7. Mizuta, H.; Kawazoe, Y.; Ogawa, K. Gastrointestinal absorption of chlorothiazide: Evaluation of a method using salicylazosulfapyridine and acetaminophen as the marker compounds of the gastrointestinal transit time in beagle dog. Chem. Pharm. Bull. 1990, 38, 2810-2813.
8. Dressman, J. B. Comparison of canine and human gastrointestinal physiology. Pharm. Res. 1986, 3, 123-131.
9. Katori, N.; Aoyagi, N.; Kojoma, S. Effects of codeine on the agitating force and gastrointestinal transit time in dogs, for use in drug absorption studies. Biol. Pharm. Bull. 1998, 21, 418-420.
10. Kondo, H.; Takahashi, Y.; Watanabe, T.; Yokohama, S.; Watanabe, J. Gastrointestinal transit of liquids in unfed cynomolgus monkeys. Biopharm. Drug Dispos. 2003, 24, 131-140.
11. Ikegami, K.; Tagawa, K.; Narisawa, S.; Osawa, T. Suitability of the cynomolgus monkey as an animal model for drug absorption studies of oral dosage forms from viewpoint of gastrointestinal physiology. Biol. Pharm. Bull. 2003, 26, 1442-1447.
12. Ward, K. W.; Smith, B. R. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab. Dispos. 2004, 32, 603-611.
13. Sakuda, S.; Akabane, T.; Teramura, T. Marked species difference in the bioavailability of midazolam in cynomolgus monkeys and humans. Xenobiotica 2006, 36, 331-340.
14. Nishimura, T.; Amano, N.; Kubo, Y.; Ono, M.; Kato, Y.; Fujita, H.; Kimura, Y.; Tsuji, A. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab. Dispos. 2007, 35, 1275-1284.
15. Prueksaritanont, T.; Gorham, M. L.; Hochman, H. J.; Tran, O. L.; Vyas, K. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in caco-2 cells. Drug Metab. Dispos. 1996, 24, 634-642.
16. Kaji, H.; Kume, T. Glucuronidation of 2-(4-chlorophenyl)-5-(2-furyl)-4- oxazoleacetic acid (TA-1801A) in humans: species differences in liver and intestinal microsomes. Drug Metab. Pharmacokinet. 2005, 20, 206-211.
17. Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
18. Fagerholm, U.; Johansson, M.; Lennernäs, H. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 1996, 13, 1336-1342.
19. Lennernäs, H.; Nylander, S.; Ungell, A. L. Jejunal permeability: A comparison between the ussing chamber technique and the single-pass perfusion in humans. Pharm. Res. 1997, 14, 667-671.
20. Watanabe, E.; Takahashi, M.; Hayashi, M. A possibility to predict the absorbability of poorly water-soluble drugs in human based on rat intestinal permeability assessed by an in vitro chamber method. Eur. J. Pharm. Biopharm. 2004, 58, 659-665.
21. Rowland, M.; Tozer, T. N. Clinical Pharmacokinetics; Concept and Application; Lea & Febiger: Philadelphia, 1980; 2
22. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10 (7), 1093-1095.
23. Goodman, L. S.; Hardman, J. G.; Limbird, L. E. Goodman & Gilman's the Pharmacological Basis of Therapeutics; 10th ed., Japanese ed.; Hirokawa Publishing Co.: Tokyo, 2003.
24. Nishimura, M.; Naito, S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab. Pharmacokinet. 2005, 20, 452-477.
25. Yamada, K.; Furuya, A.; Akimoto, M.; Maki, T.; Suwa, T.; Ogata, H. Evaluation of gastrointestinal transit controlled- beagle dog as a suitable animal model for bioavailability testing of sustained-release acetaminophen dosage form. Int. J. Pharm. 1995, 119, 1-10.
26. Amidon, G. L.; Sinko, P. J.; Fleisher, D. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 1988, 5, 651-654.
27. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 1991, 175, 880-885.
28. Yamashita, S.; Furubayashi, T.; Kataoka, M.; Sakane, T.; Sezaki, H.; Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur. J. Pharm. Sci. 2000, 10, 195-204.
29. Flanagan, S. D.; Benet, L. Z. Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum. Pharm. Res. 1999, 16, 221-224.
30. Flanagan, S. D.; Cummins, C. L.; Susanto, M.; Liu, X.; Takahashi, L. H.; Benet, L. Z. Comparion of furosemide and vinblastine secretion from cell line overexpressing multidrug resintance protein (P-glycoprotein) and multidrug resintance-associated protein (MRP1 and MRP2). Pharmacology 2002, 64, 126-134.
31. Chen, C.; Scott, D.; Hanson, E.; Franco, J.; Berryman, E.; Volberg, M.; Liu, X. Impact of MRP2 on the biliary excretion and intestinal absorption of furosemide, probenicid, and methotrexate using eisai hyperbilirubinemic rats. Pharm. Res. 2003, 20, 31-37.
32. Walle, T.; Walle, U. K.; Olanoff, L. S. Quantitative account of propranolol metabolism in urine of normal man. Drug Metab. Dispos. 1985, 13, 204-209.
33. Masubuchi, Y.; Hosokawa, S.; Horie, T.; Suzuki, T.; Ohmori, S.; Kitada, M.; Narimatsu, S. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab. Dispos. 1994, 22, 909-915.
34. 2 and cumene hydroperoxide-supported reactions. Drug Metab. Dispos. 1996, 241, 112-118.
35. Sten, T.; Qvisen, S.; Uutela, P.; Luukkanen, L.; Kostiainen, R.; Finel, M. Prominent but reverse stereoselectivity in propranolol glucuronidation by UDP-glucuronosyltransferases 1A9 and 1A10. Drug Metab. Dispos. 2006, 34, 1488-1494.
36. Sample, R. G.; Rossi, G. V.; Packman, E. W. Thiry-Vella dog as a biological model for drug absorption from the intestinal mucosa. J. Pharm. Sci. 1968, 57, 759-798.
37. Vree, T. B.; van den Biggelaar-Martea, M.; Verwey-van Wissen, C. P.; Vree, J. B.; Guelen, P. Pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Biopharm. Drug Dispos. 1993, 14, 491-502.
38. Berggren, S.; Lennernäs, P.; Ekelund, M.; Westom, B.; Hoogstraate, J.; Lennernäs, H. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. J. Pharm. Pharmacol. 2003, 55, 963-972.
39. Johnson, B. M.; Charman, W. N.; Porter, C. J. The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamil. J. Pharm. Pharmacol. 2001, 53, 1611-1619.
40. Mistry, M.; Houston, J. B. Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab. Dispos. 1987, 15, 710-717.
41. Fisher, M. B.; Paine, M. F.; Strelevitz, T. J.; Wrighton, S. A. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. 2001, 33, 273-297.
42. Ritter, J. K. Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin. Drug Metab. Toxcol. 2007, 3, 93-107.